A federal judge in Trenton has dismissed the last remaining 570 cases in multidistrict litigation over Merck’s osteoporosis drug Fosamax, but the cases could be reinstated if plaintiffs win an appeal currently pending before the U.S. Court of Appeals for the Third Circuit.

U.S. District Judge Freda Wolfson of the District of New Jersey dismissed the remaining cases after finding they were based on claims that a pre-2011 warning label on the drug failed to sufficiently warn users that the drug could cause femur fractures.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]